Anbio Biotechnology Outperforms Oncocyte in Head-to-Head Review

Anbio Biotechnology's higher revenue and earnings give it an edge over Oncocyte, according to industry analysts.

Published on Feb. 25, 2026

Got story updates? Submit your updates here. ›

Oncocyte (NASDAQ:IMDX) and Anbio Biotechnology (NASDAQ:NNNN) are both manufacturing companies, but a head-to-head review by industry analysts shows Anbio Biotechnology has the advantage. Anbio Biotechnology has higher revenue and earnings than Oncocyte, and research analysts believe Anbio Biotechnology is more favorable based on its potential upside.

Why it matters

This analysis provides valuable insights for investors looking to compare these two biotechnology companies and make informed decisions about their investments. The findings highlight Anbio Biotechnology's stronger financial performance and the research analysts' positive outlook on the company's prospects.

The details

The analysis compares Oncocyte and Anbio Biotechnology across several key metrics, including analyst recommendations, institutional ownership, profitability, valuation, and earnings. Anbio Biotechnology emerges as the stronger performer, with higher revenue and earnings than Oncocyte. Additionally, research analysts believe Anbio Biotechnology has more potential upside, with a consensus target price suggesting a 112.77% increase.

  • The analysis was published on February 25, 2026.

The players

Oncocyte Corporation

A molecular diagnostics company that researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer.

Anbio Biotechnology

A company dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products, with a focus on transforming the diagnostics landscape through personalized and decentralized solutions.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the strengths of Anbio Biotechnology, a company that has demonstrated superior financial performance and a positive outlook from industry analysts compared to its peer, Oncocyte. Investors may want to further research Anbio Biotechnology as a potential investment opportunity in the biotechnology sector.